Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares second interim results that include 100% protection against serious diseases, including hospitalization
Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares Phase 3 COVAXIN interim results, shows 81% efficiency Nasdaq: OCGN
Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares Phase 3 COVAXIN Interim Results, Shows 81% Efficiency
